Form 4: Scholar Rock COO & CFO Edward Myles Reports Stock Sales and Option Exercises

Edward Myles, COO & CFO of Scholar Rock Holding Corp, reports exercising stock options and selling shares of common stock on March 10, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On March 10, 2025, Edward Myles, the COO & CFO of Scholar Rock Holding Corp, executed multiple transactions involving the company's stock.
• Myles exercised stock options to acquire common stock at prices of $13.83, $18.08, $4.86, $10, and $15.75.
• Concurrently, Myles sold 112,897 shares at a weighted average price of $35.82 and 29,395 shares at a weighted average price of $34.87.
• These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November 19, 2024.
• Following these transactions, Myles directly owns 111,345 restricted stock units and 140,740 shares of common stock.
• The stock options exercised had various vesting schedules, with some fully vested and others vesting quarterly over several years, contingent on continued service with the company.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The filing simply reports transactions under a pre-existing trading plan. There's no inherent positive or negative signal, but the sales could be perceived negatively by some.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which can mitigate concerns about insider trading.

Negatives

• The sale of a significant number of shares by a high-ranking executive could be interpreted negatively by some investors.

Risks

• Executive stock sales can sometimes signal a lack of confidence in the company's future prospects, although this is not necessarily the case here given the pre-arranged trading plan.

Future Outlook

The document does not contain explicit forward-looking statements regarding the company's future performance.

Industry Context

Insider trading activity is always closely watched in the biotech industry, given the high-risk, high-reward nature of drug development. Transparency and adherence to regulations, such as Rule 10b5-1 trading plans, are crucial for maintaining investor confidence.

Comparison to Industry Standards

• Rule 10b5-1 trading plans are a common practice among executives in publicly traded companies, including those in the biotechnology sector, to manage their stock holdings while avoiding accusations of insider trading.
• Comparable companies such as Amgen, Biogen, and Gilead Sciences also see regular Form 4 filings from their executives, reflecting similar patterns of stock option exercises and sales.

Stakeholder Impact

• Shareholders may react to the stock sales, although the pre-arranged trading plan mitigates potential concerns.
• The transactions have no immediate impact on employees, customers, suppliers, or creditors.

Key Dates